리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 06월
페이지 정보:영문 271 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 제3세대 시퀀싱 시장은 2030년까지 25억 달러에 이를 전망
2024년에 7억 8,580만 달러로 추정되는 제3세대 시퀀싱 세계 시장은 2024-2030년간 CAGR 21.2%로 성장하여 2030년에는 25억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 제3세대 시퀀싱 제품은 CAGR 22.8%를 나타내고, 분석 기간 종료시에는 18억 달러에 이를 것으로 예측됩니다. 제3세대 시퀀싱 서비스 분야의 성장률은 분석 기간 CAGR로 17.4%로 추정됩니다.
미국 시장은 약 2억 660만 달러, 중국은 CAGR 20.0%로 성장 예측
미국의 제3세대 시퀀싱 시장은 2024년에 2억 660만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 3억 8,020만 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 20.0%로 추정됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 19.6%와 18.1%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 14.4%를 보일 전망입니다.
세계의 '제3세대 시퀀싱' 시장 - 주요 동향과 촉진요인 정리
유전체 정밀화 시대의 3세대 시퀀싱의 특징은?
3세대 시퀀싱(TGS) 기술은 증폭이 필요 없는 롱리드 1분자 시퀀싱을 제공함으로써 유전체 분석의 전망을 재정의했습니다. Pacific Biosciences의 SMRT나 Oxford Nanopore의 MinION과 같은 TGS 플랫폼은 짧은 리드와 오류를 발생시키고 쉬운 증폭 과정에 크게 의존하는 2세대 방법과는 달리, 반복 서열, 구조적 변이, 후성유전학적 변형을 포함한 복잡한 유전체 영역에 걸쳐 더 높은 충실도로 초장축 리드를 제공합니다. 이러한 능력은 특히 식물 유전체, 희귀질환 유전학, 암의 이질성 등 지금까지 어려웠던 영역에서 완전한 유전체을 de novo로 조립하는 데 필수적입니다. 연구자들은 또한 TGS를 전사체학에 적용하여 전장 mRNA 시퀀싱을 수행함으로써 대체 스플라이싱 및 이소형 발현의 정확한 검출을 가능하게 하고 있습니다. 또한, TGS는 실시간 시퀀싱을 제공하여 감염병 발생 시 또는 병원체 모니터링 및 바이오 보안에 적용하기 위해 필수적인 빠른 처리 시간을 제공합니다. 염기서열 분석 중 RNA를 직접 읽고 메틸화 패턴을 검출할 수 있기 때문에 TGS는 기초 연구와 임상 모두에서 혁신적인 기술로 자리매김하고 있습니다.
실시간 휴대용 시퀀싱은 유전체 진단의 미래인가?
휴대성과 실시간 분석은 TGS 플랫폼의 특징으로, 임상 및 현장 환경 모두에서 탁월한 유연성을 제공하며, Oxford Nanopore MinION과 같은 장치는 주머니에 넣을 수 있을 정도로 작지만, 외딴 마을, 전장, 우주 정거장 등 현장에서 복잡한 유전체 시퀀싱을 수행할 수 있을 만큼 강력합니다. 이는 공중보건, 역학, 개인 맞춤형 의료에 매우 큰 의미가 있습니다. 임상 진단에서 실시간 시퀀싱은 패혈증 관리, 병원 내 감염, 암 프로파일링에서 매우 중요한 병원균을 신속하게 식별할 수 있게 해줍니다. 돌연변이 모니터링과 공중보건 대응을 위한 지침으로 그 가치를 입증했습니다. 법의학 분야에서 TGS는 DNA 프로파일링에 새로운 차원의 정확성과 포괄성을 제공합니다. 휴대용 플랫폼은 또한 농업 과학자들이 현장에서 식물과 동물의 유전체을 모니터링하여 실시간 육종 결정, 질병 감지 및 생명 공학에 도움을 주고 있습니다. 이러한 이동성과 실시간 데이터 출력의 결합은 중앙 집중식 실험실의 필요성을 크게 줄이고, 자원이 제한된 환경에서도 고급 시퀀싱을 사용할 수 있도록 하여 분산형, 신속하고 데이터가 풍부한 진단의 문을 열어줍니다.
3세대 시퀀싱 채택을 촉진하는 기술 발전은 무엇인가?
TGS의 발전은 분자생물학, 바이오인포매틱스, 기기공학의 발전의 수렴에 의해 추진되고 있습니다. 주요 발전에는 처리량 향상, 오류율 감소, 기본 호출 알고리즘 강화 등이 포함되며, 이를 통해 TGS 플랫폼은 롱리드의 이점을 유지하면서 2세대 정확도에 필적할 수 있게 되었습니다. 새로운 효소 화학, 기공 설계 및 신호 처리 방법의 도입으로 리드 길이와 속도가 향상되었으며, 동시에 염기당 비용이 감소했습니다. 생물정보학 도구도 발전하여 TGS로 생성되는 방대하고 복잡한 데이터 세트를 처리할 수 있는 확장 가능한 솔루션을 제공하고, 클라우드 기반 플랫폼을 통해 실시간 유전체 데이터 분석 및 공유가 용이해졌습니다. 멀티플렉싱 기능이 확장되어 연구자들은 정확도를 떨어뜨리지 않고 여러 샘플을 동시에 시퀀싱할 수 있게 되었습니다. 또한, 시료 전처리 및 자동화 기술 혁신은 작업 시간과 오염 위험을 감소시키고 있습니다. 일부 TGS 도구의 개방형 플랫폼 특성은 광범위한 학술 및 산업 협력을 촉진하고 특정 용도에 대한 발견과 맞춤화를 가속화하고 있습니다. 이러한 기술적 모멘텀은 TGS를 단순히 기존 방법을 대체하는 것이 아니라, 과학 분야 전반에 걸쳐 최첨단 연구와 상업적 혁신을 가능하게 하는 만능 도구로 자리매김하고 있습니다.
3세대 시퀀싱 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다.
3세대 시퀀싱 시장의 급격한 성장은 기술, 용도, 행동 역학이 결합하여 촉진되고 있습니다. 헬스케어 분야에서는 정밀 진단 및 맞춤 치료 계획에 대한 수요가 증가함에 따라 복잡한 구조적 돌연변이, 희귀 돌연변이, 후성유전학적 마커를 검출할 수 있는 시퀀싱 도구가 필요합니다. 종양학 분야에서는 실시간 종합적인 시퀀싱을 통해 맞춤형 암 치료로의 전환이 가속화되고 있습니다. 감염 감시 분야에서 TGS는 병원균의 거의 즉각적인 유전체 분석을 가능하게 합니다. 특히 항생제 내성균 증가로 인해 이러한 필요성이 더욱 절실해지고 있습니다. 농업 분야에서는 식량 안보와 유전자 최적화 작물 개발이 식물과 동물의 유전체 분석에 TGS를 도입하는 데 박차를 가하고 있습니다. 또한, 소비자 직접 유전자 검사의 인기가 높아짐에 따라 더 깊은 통찰력을 제공하는 종합적인 시퀀싱 기술에 대한 관심이 높아지고 있습니다. 고해상도, 고처리량 유전체 과학으로의 광범위한 전환을 반영하여, 학술 기관과 생명공학 스타트업은 연구 인프라에 TGS 플랫폼을 통합하는 추세를 보이고 있습니다. 또한, 휴대용 기기를 활용한 시퀀싱의 비중앙집중화는 사용자 행동을 변화시키고, 현장 진단과 데이터 접근의 민주화를 촉진하고 있습니다. 이러한 기술 주도형 및 최종 사용자 중심의 역학이 시장의 강력한 성장 궤도를 견인하고 있습니다.
부문
컴포넌트(제품, 서비스), 테크놀러지(1분자 실시간 시퀀싱, 나노포어 시퀀싱, 합성 롱 리드 시퀀싱), 용도(유전체 시퀀싱, 에피제네틱스, 전사체학, 군유전체학, 기타 용도), 최종사용자(바이오 제약 기업, 병원 및 클리닉, 계약 연구기관, 기타 최종사용자)
조사 대상 기업 예(총 34개사)
10x Genomics
Agilent Technologies, Inc.
BGI Genomics Co., Ltd.
Complete Genomics, Inc.
Element Biosciences, Inc.
Eurofins Scientific
F. Hoffmann-La Roche AG
GATC Biotech AG
GenapSys, Inc.
Genia Technologies, Inc.
Illumina, Inc.
Loop Genomics
Nabsys, Inc.
Oxford Nanopore Technologies
Pacific Biosciences of California, Inc.
PerkinElmer, Inc.
Phase Genomics, Inc.
QIAGEN N.V.
Stratos Genomics, Inc.
Thermo Fisher Scientific Inc.
관세 영향 계수
Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 수익원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.
Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사했습니다.
Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.
2025년 4월: 협상 단계
이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.
2025년 7월: 최종 관세 재설정
고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.
상호 및 양자 간 무역과 관세의 영향 분석 :
미국 <>& 중국 <>& 멕시코 <>& 캐나다 <>&EU <>& 일본 <>& 인도 <>& 기타 176개국
업계 최고의 이코노미스트: Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트를 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
기타 유럽
아시아태평양
기타 지역
제4장 경쟁
LSH
영문 목차
영문목차
Global Third Generation Sequencing Market to Reach US$2.5 Billion by 2030
The global market for Third Generation Sequencing estimated at US$785.8 Million in the year 2024, is expected to reach US$2.5 Billion by 2030, growing at a CAGR of 21.2% over the analysis period 2024-2030. Third Generation Sequencing Products, one of the segments analyzed in the report, is expected to record a 22.8% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Third Generation Sequencing Services segment is estimated at 17.4% CAGR over the analysis period.
The U.S. Market is Estimated at US$206.6 Million While China is Forecast to Grow at 20.0% CAGR
The Third Generation Sequencing market in the U.S. is estimated at US$206.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$380.2 Million by the year 2030 trailing a CAGR of 20.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 19.6% and 18.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.4% CAGR.
What Sets Third Generation Sequencing Apart in the Era of Genomic Precision?
Third Generation Sequencing (TGS) technologies have redefined the landscape of genomic analysis by offering long-read, single-molecule sequencing without the need for amplification. This evolution from earlier sequencing technologies has profound implications for biological research, clinical diagnostics, agriculture, and evolutionary science. Unlike second-generation methods, which rely heavily on short reads and error-prone amplification processes, TGS platforms such as Pacific Biosciences’ SMRT and Oxford Nanopore’s MinION deliver ultra-long reads with higher fidelity across complex genomic regions, including repetitive sequences, structural variants, and epigenetic modifications. These capabilities are critical for assembling complete genomes de novo, especially in previously intractable areas like plant genomes, rare disease genetics, and cancer heterogeneity. Researchers are also applying TGS to transcriptomics for full-length mRNA sequencing, allowing for accurate detection of alternative splicing and isoform expression. Additionally, TGS offers real-time sequencing, enabling rapid turnaround times critical during infectious disease outbreaks and for applications in pathogen surveillance and biosecurity. The ability to directly read RNA and detect methylation patterns during sequencing positions TGS as a transformative technology in both foundational research and clinical practice.
Is Real-Time and Portable Sequencing the Future of Genomic Diagnostics?
Portability and real-time analysis are hallmarks of TGS platforms, offering unmatched flexibility in both clinical and field environments. Devices like the Oxford Nanopore MinION are compact enough to fit in a pocket yet powerful enough to perform complex genomic sequencing on-site-be it a remote village, a battlefield, or a space station. This has enormous implications for public health, epidemiology, and personalized medicine. In clinical diagnostics, real-time sequencing enables faster pathogen identification, crucial in sepsis management, hospital-acquired infections, and cancer profiling. During the COVID-19 pandemic, TGS platforms were deployed globally for real-time viral genome tracking, showcasing their value in monitoring mutations and guiding public health responses. In forensic science, TGS offers new dimensions of accuracy and comprehensiveness for DNA profiling. Portable platforms are also enabling agricultural scientists to monitor plant and animal genomes in the field, aiding in real-time breeding decisions, disease detection, and bioengineering. This mobility-combined with real-time data output-greatly reduces the need for centralized laboratories, making advanced sequencing accessible even in resource-limited settings and opening the door to decentralized, rapid, and data-rich diagnostics.
What Are the Technological Advancements Driving Adoption of Third Generation Sequencing?
The progress in TGS is driven by a convergence of improvements in molecular biology, bioinformatics, and instrument engineering. Key developments include increased throughput, reduced error rates, and enhanced basecalling algorithms that now allow TGS platforms to rival second-generation accuracy while preserving the advantages of long reads. The introduction of new enzyme chemistries, pore designs, and signal processing methods has improved read lengths and speed, while simultaneously lowering costs per base. Bioinformatics tools have also advanced, offering scalable solutions to handle the vast and complex datasets generated by TGS, with cloud-based platforms facilitating real-time genomic data analysis and sharing. Multiplexing capabilities are expanding, allowing researchers to sequence multiple samples concurrently without compromising accuracy. Additionally, innovations in sample preparation and automation are reducing hands-on time and contamination risks. The open-platform nature of some TGS tools has encouraged broad academic and industrial collaboration, accelerating discovery and customization for specific applications. This technological momentum is positioning TGS not just as a replacement for older methods, but as a versatile enabler of cutting-edge research and commercial breakthroughs across a spectrum of scientific disciplines.
The Growth in the Third Generation Sequencing Market Is Driven by Several Factors…
The rapid expansion of the third generation sequencing market is being fueled by a combination of technological, application-specific, and behavioral dynamics. In the healthcare sector, the increasing demand for precision diagnostics and personalized treatment plans is necessitating sequencing tools capable of detecting complex structural variations, rare mutations, and epigenetic markers-capabilities where TGS outperforms conventional methods. In oncology, real-time and comprehensive sequencing is accelerating the shift toward individualized cancer therapies. In infectious disease surveillance, TGS enables near-instantaneous genomic analysis of pathogens, a need that has become especially urgent with the rise of emerging and antibiotic-resistant strains. In agriculture, the push for food security and genetically optimized crops is spurring adoption of TGS in plant and animal genomics. Furthermore, the growing popularity of direct-to-consumer genetic testing is driving interest in more comprehensive sequencing technologies that offer deeper insights. Academic institutions and biotech startups are increasingly incorporating TGS platforms into their research infrastructures, reflecting a broader transition to high-resolution, high-throughput genomic science. The decentralization of sequencing-empowered by portable devices-is also transforming user behavior, encouraging point-of-care diagnostics and democratized data access. These technology-driven and end-use-specific dynamics are collectively propelling the market’s robust growth trajectory.
SCOPE OF STUDY:
The report analyzes the Third Generation Sequencing market in terms of units by the following Segments, and Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Select Competitors (Total 34 Featured) -
10x Genomics
Agilent Technologies, Inc.
BGI Genomics Co., Ltd.
Complete Genomics, Inc.
Element Biosciences, Inc.
Eurofins Scientific
F. Hoffmann-La Roche AG
GATC Biotech AG
GenapSys, Inc.
Genia Technologies, Inc.
Illumina, Inc.
Loop Genomics
Nabsys, Inc.
Oxford Nanopore Technologies
Pacific Biosciences of California, Inc.
PerkinElmer, Inc.
Phase Genomics, Inc.
QIAGEN N.V.
Stratos Genomics, Inc.
Thermo Fisher Scientific Inc.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.
We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.
As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.
To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!
APRIL 2025: NEGOTIATION PHASE
Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.
JULY 2025 FINAL TARIFF RESET
Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.
Reciprocal and Bilateral Trade & Tariff Impact Analyses:
USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.
Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.
COMPLIMENTARY PREVIEW
Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Tariff Impact on Global Supply Chain Patterns
Third Generation Sequencing - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Increasing Demand for Real-Time, Long-Read Sequencing Propels Market Growth
Accelerated Adoption in Clinical Diagnostics Expands Addressable Market
Rising Incidence of Genetic Disorders and Cancer Drives Sequencing Uptake
Demand for Deeper Genome Insights Strengthens Business Case for Third Gen Platforms
Government Genomic Initiatives and Grants Spur R&D and Market Entry
Advances in Bioinformatics Tools Enhance Accuracy and Usability of Sequencing Data
Growing Use in Agriculture and Animal Genomics Broadens Market Scope
Declining Cost per Genome Sequenced Drives Mass Adoption
Personalized Medicine Boom Throws Spotlight on Rapid Sequencing Technologies
Emerging Use Cases in Pathogen Surveillance Sustain Market Momentum
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Third Generation Sequencing Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Third Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Third Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Third Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Genome Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Genome Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for Genome Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Epigenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Epigenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for Epigenetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Transcriptomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Transcriptomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 22: World 15-Year Perspective for Transcriptomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Metagenomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Metagenomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 25: World 15-Year Perspective for Metagenomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 28: World 15-Year Perspective for Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 30: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 31: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 33: World Historic Review for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 34: World 15-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 35: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 36: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 37: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 38: World Recent Past, Current & Future Analysis for Single-molecule Real-time Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 39: World Historic Review for Single-molecule Real-time Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 40: World 15-Year Perspective for Single-molecule Real-time Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 41: World Recent Past, Current & Future Analysis for Nanopore Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 42: World Historic Review for Nanopore Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 43: World 15-Year Perspective for Nanopore Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 44: World Recent Past, Current & Future Analysis for Synthetic Long-read Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 45: World Historic Review for Synthetic Long-read Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 46: World 15-Year Perspective for Synthetic Long-read Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 47: USA Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 48: USA Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 49: USA 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
TABLE 50: USA Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 51: USA Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 52: USA 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
TABLE 53: USA Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 54: USA Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 55: USA 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
TABLE 56: USA Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 57: USA Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 58: USA 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
CANADA
TABLE 59: Canada Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 60: Canada Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 61: Canada 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
TABLE 62: Canada Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 63: Canada Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 64: Canada 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
TABLE 65: Canada Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 66: Canada Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 67: Canada 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
TABLE 68: Canada Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 69: Canada Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 70: Canada 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
JAPAN
Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 71: Japan Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 72: Japan Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 73: Japan 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
TABLE 74: Japan Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 75: Japan Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 76: Japan 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
TABLE 77: Japan Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 78: Japan Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 79: Japan 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
TABLE 80: Japan Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 81: Japan Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 82: Japan 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
CHINA
Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 83: China Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 84: China Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 85: China 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
TABLE 86: China Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 87: China Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 88: China 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
TABLE 89: China Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 90: China Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 91: China 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
TABLE 92: China Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 93: China Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 94: China 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
EUROPE
Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 95: Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 96: Europe Historic Review for Third Generation Sequencing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 97: Europe 15-Year Perspective for Third Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 98: Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 99: Europe Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 100: Europe 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
TABLE 101: Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 102: Europe Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 103: Europe 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
TABLE 104: Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 105: Europe Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 106: Europe 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
TABLE 107: Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 108: Europe Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 109: Europe 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
FRANCE
Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 110: France Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 111: France Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 112: France 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
TABLE 113: France Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 114: France Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 115: France 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
TABLE 116: France Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 117: France Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 118: France 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
TABLE 119: France Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 120: France Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 121: France 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
GERMANY
Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 122: Germany Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 123: Germany Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 124: Germany 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
TABLE 125: Germany Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 126: Germany Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 127: Germany 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
TABLE 128: Germany Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 129: Germany Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 130: Germany 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
TABLE 131: Germany Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 132: Germany Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 133: Germany 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
ITALY
TABLE 134: Italy Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 135: Italy Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 136: Italy 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
TABLE 137: Italy Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 138: Italy Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 139: Italy 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
TABLE 140: Italy Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 141: Italy Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 142: Italy 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
TABLE 143: Italy Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 144: Italy Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 145: Italy 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
UNITED KINGDOM
Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 146: UK Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 147: UK Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 148: UK 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
TABLE 149: UK Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 150: UK Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 151: UK 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
TABLE 152: UK Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 153: UK Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 154: UK 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
TABLE 155: UK Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 156: UK Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 157: UK 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 159: Rest of Europe Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 160: Rest of Europe 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 162: Rest of Europe Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 163: Rest of Europe 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
TABLE 164: Rest of Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 165: Rest of Europe Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 166: Rest of Europe 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
TABLE 167: Rest of Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 168: Rest of Europe Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 169: Rest of Europe 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 171: Asia-Pacific Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 172: Asia-Pacific 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 174: Asia-Pacific Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 175: Asia-Pacific 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
TABLE 176: Asia-Pacific Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 177: Asia-Pacific Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 178: Asia-Pacific 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
TABLE 179: Asia-Pacific Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 180: Asia-Pacific Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 181: Asia-Pacific 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
REST OF WORLD
TABLE 182: Rest of World Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 183: Rest of World Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 184: Rest of World 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
TABLE 185: Rest of World Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 186: Rest of World Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 187: Rest of World 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
TABLE 188: Rest of World Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 189: Rest of World Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 190: Rest of World 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
TABLE 191: Rest of World Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 192: Rest of World Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 193: Rest of World 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030